You are here

SARC011

Completed
SARC Global Collaboration: A phase 2 trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor for the treatment of patients with recurrent or refractory Ewing’s sarcoma, osteosarcoma, synovial sarcoma, rhabdomyo
Type of Sarcoma: 
Ewing’s sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcoma
Drug: 
R1507
Accrual Status: 
Closed
Co-Principal Investigators: 
Alberto Pappo, MD
Texas Children’s Cancer Center

Pr Gilles Vassal
Institut Gustave Roussy

For more information about this trial and open sites: